FY2026 EPS Estimates for SCYNEXIS Lowered by Analyst

SCYNEXIS, Inc. (NASDAQ:SCYX) – Stock analysts at Brookline Capital Acquisition dropped their FY2026 EPS estimates for SCYNEXIS in a note issued to investors on Monday, March 9th. Brookline Capital Acquisition analyst K. Dolliver now forecasts that the company will earn ($0.34) per share for the year, down from their prior estimate of $1.03. Brookline Capital Acquisition has a “Buy” rating on the stock. Brookline Capital Acquisition also issued estimates for SCYNEXIS’s FY2027 earnings at ($0.20) EPS, FY2028 earnings at ($0.29) EPS and FY2029 earnings at ($0.62) EPS.

A number of other equities analysts also recently issued reports on SCYX. Weiss Ratings restated a “sell (d-)” rating on shares of SCYNEXIS in a research note on Monday, December 29th. Wall Street Zen upgraded SCYNEXIS from a “hold” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $3.00.

SCYNEXIS Stock Performance

SCYX opened at $0.89 on Thursday. The stock has a market capitalization of $39.76 million, a P/E ratio of -5.24 and a beta of 1.33. The company’s 50-day simple moving average is $0.74 and its two-hundred day simple moving average is $0.76. SCYNEXIS has a 52-week low of $0.57 and a 52-week high of $1.31.

SCYNEXIS (NASDAQ:SCYX) last issued its earnings results on Wednesday, March 4th. The company reported $0.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.04). The firm had revenue of $17.20 million during the quarter, compared to analysts’ expectations of $8.10 million. SCYNEXIS had a negative return on equity of 25.52% and a negative net margin of 41.79%.

Institutional Investors Weigh In On SCYNEXIS

Institutional investors and hedge funds have recently modified their holdings of the stock. Bridgeway Capital Management LLC lifted its stake in SCYNEXIS by 4.2% in the 2nd quarter. Bridgeway Capital Management LLC now owns 368,180 shares of the company’s stock worth $248,000 after purchasing an additional 14,689 shares in the last quarter. Geode Capital Management LLC grew its position in shares of SCYNEXIS by 7.1% during the fourth quarter. Geode Capital Management LLC now owns 449,223 shares of the company’s stock valued at $284,000 after purchasing an additional 29,775 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of SCYNEXIS in the second quarter worth about $27,000. GSA Capital Partners LLP lifted its position in shares of SCYNEXIS by 95.2% in the third quarter. GSA Capital Partners LLP now owns 104,423 shares of the company’s stock worth $80,000 after buying an additional 50,916 shares in the last quarter. Finally, Sequoia Financial Advisors LLC purchased a new stake in shares of SCYNEXIS in the third quarter worth about $41,000. Institutional investors own 54.37% of the company’s stock.

More SCYNEXIS News

Here are the key news stories impacting SCYNEXIS this week:

• Positive Sentiment: Brookline Capital Acquisition raised multi‑year EPS forecasts for FY2027–FY2029 (FY2027: ($0.20) vs prior ($0.48); FY2028: ($0.29) vs ($0.30); FY2029: ($0.62) vs ($0.64)) and maintained a “Buy” rating — this signals improved medium‑term profitability expectations and analyst conviction. MarketBeat SCYX Coverage
• Positive Sentiment: SCYNEXIS announced first participants dosed in the Phase 1 IV trial of SCY‑247, its second‑generation triterpenoid antifungal candidate — clinical progress can drive long‑term value if the program advances. InsiderMonkey Article
• Neutral Sentiment: Brookline’s long‑range view includes a FY2030 EPS forecast of $0.46, implying a path to profitability several years out — bullish if achieved but distant and dependent on clinical/regulatory success. MarketBeat SCYX Coverage
• Negative Sentiment: Brookline sharply reduced FY2026 EPS from $1.03 to ($0.34), a material downward revision that suggests near‑term financial weakness or modeling changes — this is a clear negative catalyst for sentiment. MarketBeat SCYX Coverage
• Negative Sentiment: Analyst quarterly estimates from Brookline show continued quarterly losses across 2026 (Q1–Q3 at ($0.10), Q4 at ($0.05)), reinforcing the expectation of near‑term negative earnings and potential dilution or funding risk. MarketBeat SCYX Coverage

SCYNEXIS Company Profile

SCYNEXIS, Inc is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.